Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.
FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma